Mesenchymal Cell News Volume 13.27 | Jul 13 2021

    By
    Justin.choi
    -
    0
    47







    2021-07-13 | MESCN 13.27


    Mesenchymal Cell News by STEMCELL Technologies
    Vol. 13.27 – 13 July, 2021
    TOP STORY

    Morphological Screening of Mesenchymal Mammary Tumor Organoids to Identify Drugs That Reverse Epithelial-Mesenchymal Transition

    Scientists reported that cells derived from claudin-low mammary tumors, a mesenchymal subtype of triple-negative breast cancer, exhibited a distinctive organoid structure with extended “spikes” in 3D matrices.
    [Nature Communications]

    Full Article

    Survey results on the needs and challenges in the human pluripotent stem cell field
    PUBLICATIONSRanked by the impact factor of the journal

    Regional Specialization and Fate Specification of Bone Stromal Cells in Skeletal Development

    Investigators showed with mouse genetics, ex vivo cell differentiation assays, and transcriptional profiling that MSCs from bone from metaphysis and diaphysis were fundamentally distinct.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Mechanical Load Regulates Bone Growth via Periosteal Osteocrin

    Researchers identified a periosteal-osteoblast-derived secretory peptide, Osteocrin, as a mechanotransducer involved in load-induced long bone growth.
    [Cell Reports]

    Full ArticleGraphical Abstract

    A SNAI2-PEAK1-INHBA Stromal Axis Drives Progression and Lapatinib Resistance in HER2-Positive Breast Cancer by Supporting Subpopulations of Tumor Cells Positive for Antiapoptotic and Stress Signaling Markers

    MSCs and cancer-associated fibroblasts expressed high Pseudopodium-Enriched Atypical Kinase One (PEAK1) protein levels and potentiated tumorigenesis, lapatinib resistance, and metastasis of HER2-positive breast cancer cells in a PEAK1-dependent manner.
    [Oncogene]

    Full Article

    Dysregulated ECM Remodeling Proteins Lead to Aberrant Osteogenesis of Costello Syndrome iPSCs

    Scientists used Costello syndrome-induced pluripotent stem cells (iPSCs) undergoing osteogenic differentiation to investigate how dysregulation of extracellular matrix (ECM) remodeling proteins contributed to impaired osteogenesis.
    [Stem Cell Reports]

    Full Article

    M1 Macrophage-Derived Exosomes Transfer miR-222 to Induce Bone Marrow Mesenchymal Stem Cell Apoptosis

    The authors investigated the role of hypoxia/serum deprivation-induced M1-type macrophage-derived exosomes on bone marrow MSC viability, migration, and apoptosis.
    [Laboratory Investigation]

    Abstract

    Both microRNA-455-5p and -3p Repress Hypoxia-Inducible Factor-2α Expression and Coordinately Regulate Cartilage Homeostasis

    Investigators discovered that both strands of miR-455, -5p, and -3p, were up-regulated by Sox9, an essential transcription factor for cartilage differentiation and function.
    [Nature Communications]

    Full Article

    TAZ Inhibits Osteoclastogenesis by Attenuating TAK1/NF-κB Signaling

    Researchers demonstrated that global knockout and osteoclast-specific knockout of transcriptional coactivator with PDZ-binding motif (TAZ) led to a low-bone mass phenotype due to elevated osteoclast formation, which was further evidenced by in vitro osteoclast formation assays.
    [Bone Research]

    Full Article

    The B56α Subunit of PP2A Is Necessary for Mesenchymal Stem Cell Commitment to Adipocyte

    The authors reported the PP2A phosphatase B subunit B56α was specifically induced during adipocyte differentiation and mediated PP2A to dephosphorylate GSK3β, thereby blocking Wnt activity and driving adipocyte differentiation.
    [EMBO Reports]

    AbstractGraphical Abstract

    Tumor-Derived Exosomal lncRNA-SOX2OT Promotes Bone Metastasis of Non-Small Cell Lung Cancer by Targeting the miRNA-194-5p/RAC1 Signaling Axis in Osteoclasts

    Scientists found that exosomal lncRNA-SOX2OT derived from non-small cell lung cancer cells promoted cell invasion and migration in vitro, as well as bone metastasis in vivo.
    [Cell Death & Disease]

    Full Article

    The Tissue Origin of Human Mesenchymal Stem Cells Dictates Their Therapeutic Efficacy on Glucose and Lipid Metabolic Disorders in Type II Diabetic Mice

    Investigators reported a comprehensive comparison of human MSCs derived from umbilical cord Wharton’s jelly (UC-MSCs), dental pulp, and adipose tissue on the treatment of glucose and lipid metabolic disorders in type II diabetic mice.
    [Stem Cell Research & Therapy]

    Full Article

    Alterations in Cartilage Quantification before and after Injections of Mesenchymal Stem Cells Into Osteoarthritic Knees

    The authors developed a novel 3D magnetic resonance imaging analysis software program that provides “projected cartilage area ratios” for automatic detection of changes in cartilage amounts.
    [Scientific Reports]

    Full Article


    Watch the webinar where Dr. Suzan Imren discusses factors affecting the balance between HSC self-renewal and leukemic transformation
    REVIEWS

    A Paradigm Shift in Cell-Free Approach: The Emerging Role of MSCs-Derived Exosomes in Regenerative Medicine

    Scientists discuss the therapeutic potential of MSC- exosomes as an innovative approach in the context of regenerative medicine and highlight the recent knowledge on MSC- exosomes in translational medicine, focusing on in vivo researches.
    [Journal of Translational Medicine]

    Full Article

    The Potential Role of Mesenchymal Stem Cells in Modulating Anti-Aging Process

    Investigators describe in detail ways MSCs may capitalize its paracrine properties in modulating anti-aging process.
    [Cell Biology International]

    Abstract

    INDUSTRY AND POLICY NEWS

    Stem Cell Therapy Company Amniotics Raises SEK 60 Million before Deduction of Transaction Costs, in First North IPO to Advance Lead Candidate PulmoStem™ Into Clinic

    Amniotics AB has raised SEK60 million through its recent listing on Nasdaq. The funds will now be deployed to advance the company’s preclinical portfolio of cell therapy candidates based on MSC from amniotic fluid. Lead candidate PulmoStem™, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic.
    [Amniotics AB]

    Press Release

    First Ever Drug Treatment for Aggressive Pediatric Bone Disease Nears FDA Approval

    The FDA has accepted a new drug application for palovarotene, a drug identified by researchers at Children’s Hospital of Philadelphia to treat fibrodysplasia ossificans progressiva.
    [Children’s Hospital of Philadelphia]

    Press Release

    FEATURED EVENT

    ISSCR: Stem Cells – From Basic Science to Clinical Translation

    October 27 – 29, 2021
    Tokyo, Japan

    > See All Events

    JOB OPPORTUNITIES

    Laboratory Specialist – Orthopedic Research

    Marion duPont Scott Equine Medical Center – Washington, DC, United States

    Research Assistant – Immunobiology of MSCs

    Mercer University – Savannah, Georgia, United States

    Postdoctoral Researchers – Drug Discovery and Enzymology

    Florida State University – Tallahassee, Florida, United States

    Research Scientist – Biomolecular Response of MSCs

    CellDrop Biosciences – Laramie, Wyoming, United States

    Postdoctoral Fellow – Multiple Myeloma

    University of Arkansas for Medical Sciences – Little Rock, Arkansas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mesenchymal Cell News Twitter